Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 8/20 | 0.34 |
| ▸ | CTSK | P43235 | 8/20 | 0.34 |
| ▸ | CTSL | P07711 | 6/20 | 0.34 |
| ▸ | CTSB | P07858 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6020294 | 0.89 | CTSS (0.34) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6020453 | 0.88 | CTSS (0.34) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6021408 | 0.88 | SMN1; SMN2 (0.39) | CTSSCTSKCTSLCTSBHTT | |
| SCHEMBL6019181 | 0.87 | EPHX1 (0.35) | CTSSCTSKCTSLCTSBALDH1A1 | |
| SCHEMBL6020038 | 0.86 | CTSS (0.37) | CTSSCTSKCTSLCTSBHTT | |
| SCHEMBL6021379 | 0.84 | EPHX1 (0.42) | — | |
| SCHEMBL6019408 | 0.84 | KDM4E (0.33) | CTSSCTSKALDH1A1 | |
| SCHEMBL6021166 | 0.83 | CTSL (0.32) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6019681 | 0.83 | CTSS (0.50) | CTSSCTSKCTSLCTSBHTT | |
| SCHEMBL6019363 | 0.82 | TGFBR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | DHX29, HDHD5, DHRS9 | MEN1 4215/4885GAA 3708/4885KMT2A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.